ECSP099332A - Moléculas de enlace de lingo y uso farmacéutico de las mismas - Google Patents
Moléculas de enlace de lingo y uso farmacéutico de las mismasInfo
- Publication number
- ECSP099332A ECSP099332A EC2009009332A ECSP099332A ECSP099332A EC SP099332 A ECSP099332 A EC SP099332A EC 2009009332 A EC2009009332 A EC 2009009332A EC SP099332 A ECSP099332 A EC SP099332A EC SP099332 A ECSP099332 A EC SP099332A
- Authority
- EC
- Ecuador
- Prior art keywords
- binding molecule
- lingo
- same
- pharmaceutical use
- polynucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona una molécula de enlace que es capaz de enlazarse con el polipéptido LINGO de rata, de mono cinomolgo, y humano, un polinucleótido que codifica esta molécula de enlace; un vector de expresión que comprende dicho polinucleótido; un sistema de expresión que comprende un polinucleótido capaz de producir una molécula de enlace; una célula huésped aislada que comprende un sistema de expresión como se define anteriormente; el uso de esta molécula de enlace como un producto farmacéutico, en especial en el tratamiento para promover la regeneración/plasticidad axonal; una composición farmacéutica que comprende esta molécula de enlace; y un método de tratamiento de enfermedades asociadas con la degeneración y desmielinización axonal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06124350 | 2006-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099332A true ECSP099332A (es) | 2009-06-30 |
Family
ID=38325542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009332A ECSP099332A (es) | 2006-11-17 | 2009-05-15 | Moléculas de enlace de lingo y uso farmacéutico de las mismas |
Country Status (27)
Country | Link |
---|---|
US (4) | US8299221B2 (es) |
EP (2) | EP2395022A1 (es) |
JP (2) | JP5647414B2 (es) |
KR (1) | KR20090078353A (es) |
CN (2) | CN103351437A (es) |
AR (1) | AR063829A1 (es) |
AT (1) | ATE502960T1 (es) |
AU (1) | AU2007321817A1 (es) |
BR (1) | BRPI0718406A2 (es) |
CA (1) | CA2669181A1 (es) |
CL (1) | CL2007003303A1 (es) |
CO (1) | CO6180433A2 (es) |
CR (1) | CR10756A (es) |
DE (1) | DE602007013445D1 (es) |
EC (1) | ECSP099332A (es) |
ES (1) | ES2363622T3 (es) |
GT (1) | GT200900121A (es) |
IL (1) | IL198313A0 (es) |
MA (1) | MA30965B1 (es) |
MX (1) | MX2009005175A (es) |
NO (1) | NO20092331L (es) |
PE (1) | PE20081392A1 (es) |
RU (1) | RU2009122514A (es) |
TN (1) | TN2009000190A1 (es) |
TW (1) | TW200831534A (es) |
WO (1) | WO2008058736A1 (es) |
ZA (1) | ZA200902409B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5341311B2 (ja) | 2003-03-19 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogoレセプター結合タンパク質 |
PL1776136T3 (pl) | 2004-06-24 | 2013-03-29 | Biogen Ma Inc | Leczenie stanów związanych z demielinizacją |
CN101495509B (zh) | 2005-07-08 | 2015-04-22 | 比奥根艾迪克Ma公司 | Sp35抗体及其用途 |
NZ598421A (en) * | 2005-12-02 | 2013-11-29 | Biogen Idec Inc | Treatment of Conditions Involving Demyelination |
JP2009544703A (ja) | 2006-07-24 | 2009-12-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Sp35またはTrkAアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
AU2008311251B9 (en) * | 2007-10-11 | 2014-04-17 | Biogen Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists |
EP2217697B1 (en) * | 2007-11-08 | 2015-06-10 | Biogen MA Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
JP2011527572A (ja) | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Lingo抗体または断片を含む組成物 |
CA2797093C (en) | 2010-04-26 | 2019-10-29 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
CN103096910A (zh) | 2010-04-27 | 2013-05-08 | Atyr医药公司 | 与苏氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
US8993723B2 (en) | 2010-04-28 | 2015-03-31 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases |
AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
WO2011139907A2 (en) | 2010-04-29 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
JP6039546B2 (ja) | 2010-05-03 | 2016-12-07 | エータイアー ファーマ, インコーポレイテッド | セリルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
EP2566495B1 (en) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
WO2011140135A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
AU2011248355B2 (en) * | 2010-05-03 | 2017-01-19 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases |
JP6008843B2 (ja) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | グルタミル−プロリルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
EP2566499B1 (en) | 2010-05-04 | 2017-01-25 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
AU2011252990B2 (en) | 2010-05-14 | 2017-04-20 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
US9034598B2 (en) | 2010-05-17 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
JP6046607B2 (ja) | 2010-05-27 | 2016-12-21 | エータイアー ファーマ, インコーポレイテッド | グルタミニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CN103118694B (zh) | 2010-06-01 | 2016-08-03 | Atyr医药公司 | 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
CA2804424C (en) | 2010-07-12 | 2021-03-30 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
CA2804416C (en) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
KR102099730B1 (ko) | 2010-07-12 | 2020-04-16 | 에이티와이알 파마, 인코포레이티드 | 아스파르틸trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견 |
CA2808539C (en) | 2010-08-25 | 2021-05-25 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
WO2012048125A2 (en) | 2010-10-06 | 2012-04-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases |
WO2013022982A2 (en) | 2011-08-09 | 2013-02-14 | Atyr Pharma, Inc. | Pegylated tyrosyl-trna synthetase polypeptides |
WO2013086228A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Pegylated aspartyl-trna synthetase polypeptides |
WO2013086216A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Improved aspartyl-trna synthetases |
CN104220461A (zh) | 2011-12-29 | 2014-12-17 | Atyr医药公司 | 天冬氨酰-tRNA合成酶-FC缀合物 |
US9248128B2 (en) | 2012-01-27 | 2016-02-02 | New York University | Method for enhancing remyelination using GLI1 inhibitors |
US9796780B2 (en) * | 2012-05-14 | 2017-10-24 | Biogen Ma Inc. | LINGO-2 antagonists for treatment of conditions involving motor neurons |
AU2014233436B2 (en) | 2013-03-15 | 2019-12-05 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
WO2016112270A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
KR102399454B1 (ko) * | 2015-01-26 | 2022-05-19 | 애플 인크. | 수평 및 수직 위치확인 정확도 |
BR112019000630A2 (pt) * | 2016-07-13 | 2019-07-09 | Biogen Ma Inc | regimes de dosagem dos antagonistas de lingo-1 e usos para tratamento de distúrbios desmielinizante |
EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
KR102414826B1 (ko) | 2020-06-18 | 2022-06-30 | 삼성전기주식회사 | 코일 부품 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
UA34415C2 (uk) | 1989-02-13 | 2001-03-15 | Шерінг Аг Берлін Унд Бергкамен | Істотно чистий білок, що є тромболітиком, виділена днк, що його кодує, культура яйцеклітин xenopus laevis, трансформованих вектором, спосіб одержання активатора плазміногена, лікарський тромболітичний засіб |
JP5341311B2 (ja) | 2003-03-19 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogoレセプター結合タンパク質 |
CN1798840B (zh) * | 2003-03-19 | 2010-11-10 | 比奥根艾迪克Ma公司 | Nogo受体结合蛋白 |
US20050214288A1 (en) * | 2004-03-26 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies against Nogo receptor |
PL1776136T3 (pl) * | 2004-06-24 | 2013-03-29 | Biogen Ma Inc | Leczenie stanów związanych z demielinizacją |
CN101495509B (zh) | 2005-07-08 | 2015-04-22 | 比奥根艾迪克Ma公司 | Sp35抗体及其用途 |
-
2007
- 2007-11-15 DE DE602007013445T patent/DE602007013445D1/de active Active
- 2007-11-15 ES ES07846601T patent/ES2363622T3/es active Active
- 2007-11-15 AU AU2007321817A patent/AU2007321817A1/en not_active Abandoned
- 2007-11-15 EP EP11151300A patent/EP2395022A1/en not_active Withdrawn
- 2007-11-15 CA CA002669181A patent/CA2669181A1/en not_active Abandoned
- 2007-11-15 KR KR1020097009952A patent/KR20090078353A/ko not_active Application Discontinuation
- 2007-11-15 EP EP07846601A patent/EP2084190B1/en not_active Revoked
- 2007-11-15 PE PE2007001587A patent/PE20081392A1/es not_active Application Discontinuation
- 2007-11-15 MX MX2009005175A patent/MX2009005175A/es not_active Application Discontinuation
- 2007-11-15 AT AT07846601T patent/ATE502960T1/de not_active IP Right Cessation
- 2007-11-15 JP JP2009536654A patent/JP5647414B2/ja not_active Expired - Fee Related
- 2007-11-15 RU RU2009122514/10A patent/RU2009122514A/ru not_active Application Discontinuation
- 2007-11-15 CN CN2013102559773A patent/CN103351437A/zh active Pending
- 2007-11-15 CN CN2007800415830A patent/CN101553506B/zh not_active Expired - Fee Related
- 2007-11-15 AR ARP070105078A patent/AR063829A1/es not_active Application Discontinuation
- 2007-11-15 US US12/514,542 patent/US8299221B2/en not_active Expired - Fee Related
- 2007-11-15 BR BRPI0718406-9A patent/BRPI0718406A2/pt not_active IP Right Cessation
- 2007-11-15 WO PCT/EP2007/009880 patent/WO2008058736A1/en active Application Filing
- 2007-11-16 TW TW096143597A patent/TW200831534A/zh unknown
- 2007-11-16 CL CL200703303A patent/CL2007003303A1/es unknown
-
2009
- 2009-04-07 ZA ZA200902409A patent/ZA200902409B/xx unknown
- 2009-04-23 IL IL198313A patent/IL198313A0/en unknown
- 2009-04-29 CR CR10756A patent/CR10756A/es not_active Application Discontinuation
- 2009-05-12 GT GT200900121A patent/GT200900121A/es unknown
- 2009-05-12 CO CO09048055A patent/CO6180433A2/es not_active Application Discontinuation
- 2009-05-15 EC EC2009009332A patent/ECSP099332A/es unknown
- 2009-05-15 TN TNP2009000190A patent/TN2009000190A1/fr unknown
- 2009-06-03 MA MA31944A patent/MA30965B1/fr unknown
- 2009-06-17 NO NO20092331A patent/NO20092331L/no not_active Application Discontinuation
-
2012
- 2012-09-14 US US13/616,226 patent/US20130071400A1/en not_active Abandoned
- 2012-10-04 JP JP2012222370A patent/JP2013056888A/ja active Pending
-
2013
- 2013-09-26 US US14/037,841 patent/US20140037639A1/en not_active Abandoned
-
2014
- 2014-05-19 US US14/280,933 patent/US20140255415A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099332A (es) | Moléculas de enlace de lingo y uso farmacéutico de las mismas | |
BR112014022708A8 (pt) | uso de uma proteína ligante de neurotrofina p75ntr, uso de uma molécula de ácido nucleico, uso de um vetor de expressão replicável, célula hospedeira, composição farmacêutica e kit | |
BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
CL2007003635A1 (es) | Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer. | |
CL2009000035A1 (es) | Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras. | |
CL2008000348A1 (es) | Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis. | |
BRPI0905733B8 (pt) | composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica | |
BR112017015773A2 (pt) | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo | |
BRPI0713000A8 (pt) | Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples | |
BR112015008347A2 (pt) | molécula de anticorpo isolada, uso de dita molécula de anticorpo, composição, ácido nucleico isolado, célula hospedeira, métodos para produção de uma molécula de anticorpo, para produzir um domínio de ligação de antígeno ao anticorpo para a?1-42 humano e para produzir um membro de ligação que se liga a a?1-42 humana. | |
BR112014032316A2 (pt) | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta | |
AR083715A1 (es) | Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas | |
BR112015002765A2 (pt) | proteína de fusão, polinucleotídeo, vetor, célula hospedeira, métodos para produzir a proteína de fusão, de tratamento de uma doença em um indivíduo e para ativação seletiva in vitro ou in vivo de células reguladoras, composição farmacêutica, uso da proteína de fusão e invenção. | |
DOP2010000368A (es) | Inmunoglobulinas con dominio variable dual y usos de la misma | |
AR061171A1 (es) | Proteinas de union al factor de crecimiento de hepatocitos (fch) | |
CL2008000670A1 (es) | Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras. | |
WO2008028117A3 (en) | Glp-2 mimetibodies, polypeptides, compositions, methods and uses | |
BR112012009432A2 (pt) | anticorpo anti-hsv | |
CO6280490A2 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
AR092465A1 (es) | Moleculas de union a il-18 | |
DOP2007000043A (es) | Derivados de cromanol sustituidos y su uso | |
CL2007003765A1 (es) | Compuestos derivados de 2-oxo-4-hidroxi-benzotiazol; procesode preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, bronquitis, asma y bronquiectasias. | |
BRPI0506888A (pt) | composições de suplemento lìquido compreendendo um ou mais medicamentos | |
CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
BR112012000115B8 (pt) | composição compreendendo aminoácidos e/ou peptídeos bioativos e óleo marinho em uma emulsão óleo-em-água estável, processo para a produção e seus usos |